Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan + Capecitabine + Bevacizumab in 2nd-line mCRC
NCT06192680Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Apr 2024
- Primary completion
- Nov 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in metastatic colorectal cancer (mCRC), sponsored by Harbin Medical University. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06192680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192680.